We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+10.86%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$5.06B
AUM Growth
–
Cap. Flow
+$4.02B
Cap. Flow %
79.47%
Top 10 Hldgs %
79.91%
Holding
75
New
67
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$880M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$674M
3
GHDX
Genomic Health, Inc.
GHDX
+$448M
4
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$420M
5
INCY icon
Incyte
INCY
+$324M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 48.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGYP
26
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$11.3M 0.22%
+2,644,787
New +$13.3M
CHTP
27
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
$11M 0.22%
+4,775,787
New +$9.66M
PTLA
28
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$9.83M 0.19%
+399,914
New +$7.95M
INSM icon
29
Insmed
INSM
$27.5B
$9.52M 0.19%
+795,803
New +$8.13M
IRWD icon
30
Ironwood Pharmaceuticals
IRWD
$709M
$9.16M 0.18%
+1,101,059
New +$13.3M
BCRX icon
31
BioCryst Pharmaceuticals
BCRX
$2.44B
$8.62M 0.17%
+5,563,615
New +$9.6M
MTEM
32
DELISTED
Molecular Templates, Inc.
MTEM
$8.39M 0.17%
+9,667
New +$8.17M
MDGL icon
33
Madrigal Pharmaceuticals
MDGL
$11.9B
$6.98M 0.14%
+39,973
New +$10.4M
ARRY
34
DELISTED
Array Biopharma Inc
ARRY
$6.81M 0.13%
+1,500,000
New +$8.07M
QLTI
35
DELISTED
QLT Inc
QLTI
$6.74M 0.13%
+1,535,863
New +$12.4M
IONS icon
36
Ionis Pharmaceuticals
IONS
$9.93B
$6.64M 0.13%
+247,036
New +$5.25M
CCXI
37
DELISTED
ChemoCentryx, Inc.
CCXI
$5.3M 0.1%
+375,000
New +$4.86M
AMBI
38
DELISTED
Ambit Biosciences Corp
AMBI
$5.24M 0.1%
+747,962
New +$5.35M
XNPT
39
DELISTED
XENOPORT, INC.
XNPT
$5.12M 0.1%
+1,034,112
New +$6.27M
ANAC
40
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$4.9M 0.1%
+876,463
New +$5.31M
PRTA icon
41
Prothena Corp
PRTA
$485M
$4.77M 0.09%
+369,650
New +$3.44M
KYTH
42
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$4.46M 0.09%
+165,000
New +$3.78M
ACHN
43
DELISTED
Achillion Pharmaceuticals
ACHN
$3.72M 0.07%
+455,000
New +$3.47M
PBYI icon
44
Puma Biotechnology
PBYI
$477M
$3.7M 0.07%
+83,333
New +$2.94M
LITS
45
Lite Strategy Inc
LITS
$33.7M
$3.68M 0.07%
+25,781
New +$4.29M
BDSI
46
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$3.66M 0.07%
+900,505
New +$4.23M
ZGNX
47
DELISTED
Zogenix, Inc.
ZGNX
$3.42M 0.07%
+250,125
New +$3.2M
SLXP
48
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$3.02M 0.06%
+45,571
New +$2.61M
ACGN
49
DELISTED
Aceragen Inc
ACGN
$2.95M 0.06%
+33,121
New +$2.98M
ASMB icon
50
Assembly Biosciences
ASMB
$700M
$2.92M 0.06%
+20,264
New +$3.18M
1
2
3

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for Julian Baker, which disclosed 75 positions worth $5.06B. Its ten largest holdings account for 80% of the portfolio.

Its largest position is PHARMACYCLICS INC: 10,771,138 shares worth $856M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets.

  • Julian Baker's largest Q2 2013 buy was PHARMACYCLICS INC: 10,771,138 shares worth $856M.
  • Julian Baker's ten largest holdings make up 80% of its $5.06B portfolio in Q2 2013.
  • Julian Baker disclosed 75 positions in Q2 2013, its first 13F filing on record.

Based on Baker Bros. Advisors's 13F filing for Q2 2013, filed 14 Aug 2013.